about
Biosimilar Insulins: Basic ConsiderationsAn update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin.Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.Design of non-standard insulin analogs for the treatment of diabetes mellitusLong-acting basal insulin analogs: latest developments and clinical usefulness.Growth effects of insulin and insulin analogues.Analytic review: glucose controversies in the ICU.Controversies in the use of insulin analogues.Biosimilar insulins.Evolution of insulin development: focus on key parameters.The need for better insulin therapy.Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor?The use of insulin detemir during pregnancy: a safety evaluation.Pharmacologic treatment of type 2 diabetes: injectable medications.A mutated glucagon-like peptide-1 with improved glucose-lowering activity in diabetic mice.Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 3. Early plasma insulin determinations.Glargine and degludec: Solution behaviour of higher dose synthetic insulins.Effect of insulin analogues on 3t3-l1 adipogenesis and lipolysis.Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
P2860
Q28646059-BFF37C7D-4C85-402E-B54A-88F84709DFE3Q33902616-1085E471-0DEF-48CD-96ED-2AE8B9EE9941Q33959945-F7A3C51E-78E5-4C4D-A9E5-0AAF06908A19Q35988978-1AFDED43-B91B-422C-9B3D-4627C890F8B1Q36374363-AA5E65BC-9EB2-46A6-9E11-2026801477D9Q36515474-375737BF-139A-489B-AB7B-7C8408ECC16EQ37503141-D7DC47C7-DFE7-4C1E-9902-0F6AEF5F9CF1Q37813868-B3983904-8EC3-450A-8A68-3779B0A6CBF3Q37827161-F00D4325-327C-4EB0-A7E8-E28A5224A578Q38009872-3B6228DB-D467-4A68-A7BD-C204D044D37AQ38030454-1875560E-7FA0-4776-A80B-0093CE64BD2EQ38085331-974F65D6-99C9-42B1-8242-AE95C5DB9907Q38175354-B5395B51-8775-4432-B401-8FF63C9FB9E1Q38239532-16D396CE-C05D-46C9-857C-0D2D35884327Q38366782-03EFE6DE-3C67-4BD0-9BB0-3D7512CDA3C9Q38388602-5BD9A08A-83C0-4724-8C0D-39C1FC447E3AQ39452073-DD57AF12-E40D-4330-B81C-E85AA319F8A6Q39912931-D771A582-93C9-4B77-A6E9-E8F4517AE84BQ41260941-FCC2FE06-E43A-45A7-A2D8-676CE872D299Q42813894-7BFA24DC-35DD-433A-9096-939813295233Q44027980-500A547D-8ACD-4E9D-A140-BAAC479E9C0A
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Novel insulin analogues and its mitogenic potential.
@ast
Novel insulin analogues and its mitogenic potential.
@en
type
label
Novel insulin analogues and its mitogenic potential.
@ast
Novel insulin analogues and its mitogenic potential.
@en
prefLabel
Novel insulin analogues and its mitogenic potential.
@ast
Novel insulin analogues and its mitogenic potential.
@en
P2860
P1476
Novel insulin analogues and its mitogenic potential.
@en
P2093
Philip Raskin
P2860
P304
P356
10.1111/J.1463-1326.2005.00567.X
P577
2006-11-01T00:00:00Z